J. Fourcade

发表

T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2014 .

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Hong Wang, Joe-Marc Chauvin, Ornella Pagliano, 2013, Cancer research.

Breast Cancers TRAG-3 in Patients with Melanoma and T Cell Responses against + Spontaneous CD 4 Maillere and

J. Kirkwood, H. Zarour, A. Brufsky, 2006 .

Human Tumor Antigen-Specific Helper and Regulatory T Cells Share Common Epitope Specificity but Exhibit Distinct T Cell Repertoire

J. Kirkwood, H. Zarour, P. Kúdela, 2010, The Journal of Immunology.

RepertoireSpecificity but Exhibit Distinct T Cell Regulatory T Cells Share Common Epitope Human Tumor Antigen-Specific Helper and

J. Kirkwood, H. Zarour, P. Kúdela, 2010 .

Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

J. Kirkwood, H. Zarour, A. Donnenberg, 2008, Journal of immunotherapy.

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1

J. Kirkwood, H. Zarour, S. Ferrone, 2009, The Journal of Immunology.

Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers1

J. Kirkwood, H. Zarour, A. Brufsky, 2006, The Journal of Immunology.

Strategies to reverse melanoma-induced T-cell dysfunction.

H. Zarour, J. Fourcade, 2013, Clinics in dermatology.

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

J. Verweij, A. Sparreboom, W. Loos, 2004, British Journal of Cancer.

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

Epitope Hierarchy of Spontaneous CD4+ T Cell Responses to LAGE-1

J. Kirkwood, H. Zarour, B. Maillère, 2011, The Journal of Immunology.

Relationships between catecholamine or 3-methoxy 4-hydroxy phenylglycol changes and the mental performance under submaximal exercise in man

J. Lacour, L. Peyrin, J. Pequignot, 2004, Psychopharmacology.

In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase.

M. Egorin, G. Forrest, S. Musser, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

J. Kirkwood, H. Zarour, V. Kuchroo, 2010, The Journal of experimental medicine.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015, The Journal of clinical investigation.

Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients1

J. Kirkwood, H. Zarour, M. Amicosante, 2007, The Journal of Immunology.

Melanoma Patients inImmunodominant Tumor-Derived Epitope T Cells against One + Cross-Reactive CD 4

J. Kirkwood, H. Zarour, M. Amicosante, 2007 .

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012, Cancer research.

Microenvironment and Immunology CD 8 þ T Cells Speci fi c for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Ornella Pagliano, J. Kirkwood, H. Zarour, 2012 .

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015, Cancer research.

IL 10 and PD-1 Cooperate to Limit the Activity of Tumor-Speci fi c CD 8 þ T Cells

Joe-Marc Chauvin, Ornella Pagliano, J. Kirkwood, 2015 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, JCI insight.

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL).

D. Davar, Joe-Marc Chauvin, Ornella Pagliano, 2016 .

Targeting PD-1 and Tim-3 pathways to reverse tumor antigen-specific CD4+ T cell dysfunction in patients with advanced melanoma (66.1)

J. Kirkwood, H. Zarour, V. Kuchroo, 2011, Journal of Immunology.

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma.

Joe-Marc Chauvin, Ornella Pagliano, Hong Wang, 2015 .

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

D. Davar, Joe-Marc Chauvin, Carmine Menna, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.